Clearside Biomedical, Inc. announced that it will conduct a randomized, controlled, double-masked, Phase 2b clinical trial, called ODYSSEY, in wet AMD participants. Based on the draft guidance on wet AMD drug development released on February 24, 2023, by the U.S. Food & Drug Administration (FDA), plan to adjust trial design to use on-label aflibercept dosing in the comparator arm of ODYSSEY. The company expects a seamless transition to this adjusted trial design and plan to open trial enrollment in the second quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 USD | 0.00% | +4.80% | +11.97% |
May. 13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
May. 09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.97% | 97.9M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Announces Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Second Quarter of 2023